吸入性三联药物治疗慢性阻塞性肺疾病的研究进展  

Research Progress of Inhaled Triple Drugs in the Treatment of Chronic Obstructive Pulmonary Disease

作　　者：周明娅 ZHOU Mingya(Department of Pidmonary,Chongqing Qijiang District Hospital of Traditional Chinese Medicine,Qijiang Chongqing,401420,China)

机构地区：[1]重庆市綦江区中医院肺病科,重庆綦江401420

出　　处：《反射疗法与康复医学》2021年第18期175-178,共4页Reflexology And Rehabilitation Medicine

摘　　要：慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)属于呼吸系统疾病,具有较高的致死率及致残率.2021年,COPD全球倡议中提出,吸入性三联药物在改善中重度COPD患者的肺功能、提升其生活质量以及降低其急性加重发生率方面具有良好的优势.三联药物具体是指吸入性糖皮质激素、长效抗胆碱能药物和长效β_(2)受体激动剂,各自的作用机制不同,可优势互补.该文主要对COPD稳定期及急性期的治疗、吸入性三联药物的治疗机制及疗效的研究进展进行了综述,为增强对COPD患者的病情管理水平提供借鉴.Chronic obstructive pulmonary disease(COPD)is a respiratory disease with a high fatality rate and disability rate.In 2021,the COPD Global Initiative proposed that inhaled triplet drugs have good advantages in improving lung function,improving quality of life,and reducing the incidence of acute exacerbations in patients with moderate to severe COPD.The triplet drugs specifically refer to inhaled glucocorticoids,long-acting anticholinergic drugs and long-actingβ_(2) receptor agonists,and their respective mechanisms of action are different,and their advantages can complement each other.This article mainly reviews the research progress in the treatment of stable and acute phases of COPD,and the therapeutic mechanism and efficacy of inhaled triple drugs,in order to provide a reference for enhancing the management of COPD patients.

关 键 词：慢性阻塞性肺疾病 吸入性三联药物 作用机制 疗效 研究进展 

分 类 号：R56[医药卫生—呼吸系统]